A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

A Phase 1, Single Dose, Open-Label, Three-Period, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Subjects

The purpose of this study is to determine the effect of food on the pharmacokinetics (how the drug concentrations change over time) of abiraterone acetate 1000 mg when administered as a single dose in healthy male volunteers.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Treatment A: abiraterone acetate; Drug: Treatment B: abiraterone acetate; Drug: Treatment C: abiraterone acetate

Detailed Description

This is an open-label (identity of assigned study drug will be known), randomized (treatment sequences will be assigned by chance) study of a single dose of abiraterone acetate 1000 mg administered orally (by mouth) in approximately 36 healthy male participants under fasted and fed conditions. Three doses of abiraterone acetate will be administered with a 7-day washout period between each dose. The total study duration for each participant will be 21 days. Participants will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA): Treatment A = abiraterone acetate 1000 mg administered after a high-fat meal; Treatment B = abiraterone acetate 1000 mg administered after a low-fat meal; Treatment C = abiraterone acetate 1000 mg administered in the fasted state. No food will be ingested for 4 hours post-dose. Participants will be confined at the clinical research unit from the day prior to dosing until clinic discharge on the day following dosing in each treatment period. Serial pharmacokinetic samples will be collected and safety will be monitored throughout the study.

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• In good general health as determined by no clinically significant findings on medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory measurements
• Body mass index within 18 kg/m2 to 32 kg/m2, inclusive
• Non-tobacco users
• Clinical laboratory values within protocol-defined parameters
• Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]),and negative human immunodeficiency virus (HIV) antibody screens
• Negative test for selected drugs of abuse
• Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

• Significant history or manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological or psychiatric disorder, as determined by the Principal Investigator
• History or presence of an abnormal electrocardiogram
• History of stomach or intestinal surgery resection that would potentially alter absorption and/or excretion of orally administered drugs
• Screening serum total testosterone of <200 ng/dL
• History of hypersensitivity reaction to the study drug, related compounds or excipients used in the formulation
• Receipt of an investigational drug within 5 half-lives or 30 days prior to Day -1, whichever is longer
• Abnormal diet during the 30 days prior to Day 1
• Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day -1
• Planned donation of blood or plasma from Screening through Study Completion, Day 21
• Receipt of blood products within 2 months prior to Day 1
• History of protocol-defined alcohol abuse
• Known or suspected use of illicit drugs within the last year
• Use of any medication on a chronic basis
• Use of any prescription medications/products or over-the-counter non-prescription preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by the Sponsor
• Consumption of alcohol-containing foods or beverages within 24 hours prior to the first Check-in (Day -1)
• Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion (Day21)
• Consumption of caffeine-containing or grapefruit-containing foods or beverages within 72 hours prior to Day -1
• Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or beverages from Day -1 through Study Completion (Day21)
• Presence of sexual dysfunction or any medical condition that would affect sexual function
• Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for the duration of the study
• Presence of any condition that, in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in this study
• Unwillingness to refrain from using any tobacco or nicotine-containing products during screening and throughout the study to Study Completion (Day 21)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence ABC	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Experimental: Sequence ACB	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Experimental: Sequence BAC	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Experimental: Sequence BCA	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Experimental: Sequence CAB	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
Experimental: Sequence CBA	Drug: Treatment A: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal; Drug: Treatment B: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal; Drug: Treatment C: abiraterone acetate; 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Maximum observed concentration of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose
Time to maximum concentration of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose
Area under the concentration-time curve from time 0 to the last measurable concentration of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose
Area under the concentration-time curve extrapolated to infinity of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose
Apparent plasma terminal elimination rate constant of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose
Apparent terminal elimination half-life of abiraterone	Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants affected by an adverse event	Up to Day 21

Collaborators and Investigators

• Sponsor: Cougar Biotechnology, Inc.

Study record dates

Study Major Dates

• Study Start: September 1, 2009
• Primary Completion (Actual): October 1, 2009
• Study Completion (Actual): October 1, 2009

Study Registration Dates

• First Submitted: October 22, 2012
• First Submitted That Met QC Criteria: February 22, 2013
• First Posted (Estimate): February 26, 2013

Study Record Updates

• Last Update Posted (Estimate): February 26, 2013
• Last Update Submitted That Met QC Criteria: February 22, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Keywords: Healthy volunteers; Pharmacokinetics; Abiraterone acetate
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Steroid Synthesis Inhibitors; Abiraterone Acetate
• Other Study ID Numbers: CR016960; COU-AA-009 (Other Identifier: Cougar Biotechnology, Inc.)